Jeff Geschwind
About
About Dr. Jeff Geschwind, MD
Get to know the inspiring journey of Dr. Jeff Geschwind, a global leader in oncology and interventional radiology.
He is currently the Director of Oncology at USA Vein Clinics where he is responsible for the development of specialized centers dedicated to the care of cancer patients using minimally invasive image –guided procedures, known as interventional oncology procedures.
Educational Journey and Expertise
From the University of Pennsylvania to Johns Hopkins and Yale, Dr. Geschwind’s academic and professional path reflects his dedication to advancing medicine.
He has devoted the last decade of his career to the development of Interventional Oncology both as a professor at Johns Hopkins University and at Yale School of Medicine during his tenure as Chairman of the Department of Radiology and Biomedical Imaging. Dr. Geschwind is considered a pioneer and father of the field of Interventional Oncology, now considered the fourth pillar of oncology (along with medical, surgical and radiation), and founded the World Conference on Interventional Oncology in 2005, which is now the official meeting of the newly formed Society of Interventional Oncology, for which he served as its first President. These outpatient Interventional Oncology Centers will contribute to improving the lives of thousands of cancer patients and provide such patients access to cutting edge Interventional Oncology procedures, provided in an outpatient setting, thereby decreasing costs dramatically.
Leadership in Medical Innovation
With pivotal roles at NAMSA, USA Clinics Group, and Philips Healthcare, Dr. Jeff Geschwind is driving advancements in oncology and medical technology.
As a physician, he concentrated his efforts on treating hepatic cancer and more generally, focused on the nascent field of Interventional Oncology, which he helped develop into a major new field of medicine. He founded the Center of Oncologic Interventions, which utilized revolutionary imaging technology in collaboration with Philips Health Care (partly supported by funding from the NIH) to visualize tumors, target them with exquisite precision and as a result treat them more effectively. After having received an RO1 grant from the NIH in 2005, he also established his research laboratory focusing on cancer therapeutics that specifically block tumor glycolysis in cancer cells. In 2008, he received a $1.4 million philanthropic donation to further support this research. In 2009, he founded a company based on this technology and has raised $5M towards the goal of starting Phase I clinical trials for liver and pancreas cancer. He is recognized worldwide as a key opinion leader in the field of liver cancer (hepatocellular carcinoma) and has received numerous foundation, industry and federal grants for his research in the field.
Awards and Honors
Discover the accolades and honors Dr. Jeff Geschwind has earned for his unparalleled contributions to medicine and research.
As a testament to his scientific success and accomplishments, Dr. Geschwind has received numerous national and international awards throughout his career including among others, the Annual Memorial Award from the Association of University Radiologists, the Alexander Margulis Award for Excellence in Research, the Society of Interventional Radiology Gary Becker Young Investigator Award, the American Society of Clinical Oncology Merit Award, the American Roentgen Ray Society Fellowship Award, the Boston University School of Medicine and the University of California San Francisco Department of Radiology Alumni Award, the Ernest Ring Academic Development Program from the Society of Interventional Radiology and the Wilhelm Conrad Roentgen Honorary Award from the European Society of Radiology. Most recently, he was recognized by Marquis Who’s Who organization for his scientific accomplishments during his career and awarded the Albert Nelson Marquis Lifetime Achievement Award. In 2012, he was inducted into the Academy of Radiology Research from the Radiology Society of North America, the highest recognition for radiologists. He has been on the editorial board of many scientific journals including Radiology, Cardiovascular and Interventional Radiology, the Journal of Vascular and Interventional Radiology, Anticancer Research and has been a reviewer for many additional journals including Lancet, Cancer Research, Hepatology and the Journal of Clinical Oncology. He recently joined the editorial board of the journals “Diagnostics”, “Gastroenterology Insights” and “Frontiers in Oncology”.
Innovator in Cancer Research and Treatment
Dr. Jeff Geschwind has spearheaded clinical trials, developed novel cancer drugs, and introduced revolutionary interventional oncology procedures.
Dr. Geschwind is recognized internationally as an expert and key opinion leader in liver cancer. He was the lead or co-investigator on more than 50 clinical trials testing innovative treatments for patients with liver cancer funded by pharmaceutical companies, foundations and/or the NIH. Some of these trials were care changing. He also received multiple patents for research on a new promising drug that targets a specific pathway in cancer cells, which allowed him to create a company based on this discovery.
A Legacy of Excellence
With nearly 300 published manuscripts, numerous patents, and key contributions to medical textbooks, Dr. Geschwind’s work sets the gold standard in radiology and oncology.
Dr. Geschwind was visiting professor and has given numerous lectures and keynote speeches including named lectures at various prestigious institutions such as (among others) the NIH, Memorial Sloan Kettering Cancer Center, University of Pennsylvania, MD Anderson Cancer Center, the University of Michigan, Georgetown University, Brown University, Yonsei University, Seoul National University, Malaysia Cancer Center, and the Chinese University of Hong Kong. Dr. Geschwind has also been recognized as a Top Doctor by US News and World Report. He is a diplomate of the American Board of Radiology since 1998 and holds medical licenses in the states of Connecticut and New York.